CXCL8 and COVID-19: Previous studies found that thymosin drugs could inhibit the inflammatory/activated state of monocytes in the treatment of COVID-19 by reducing the release of proinflammatory mediators such as TNF-α, IL-6 and IL-8, and promote the generation of anti-inflammatory cytokines such as IL-10 [14].